This study investigated the expression of CTLA-4 and FOXP3 in CD4+CD25+ Treg cells, and CD40 and CD192 in monocyte subpopulations in PPMS (ocrelizumab treated and untreated) subjects compared to healthy controls. This evidence concerns the gene FOXP3 and primary progressive multiple sclerosis.